Propofol dose and efficacy of defibrillation testing during implantation of subcutaneous implantable cardioverter‐defibrillators: A retrospective, single center cohort study-Reference-Cited by-同舟云学术

Propofol dose and efficacy of defibrillation testing during implantation of subcutaneous implantable cardioverter‐defibrillators: A retrospective, single center cohort study

Published:2022-12-09 Issue:2 Volume:34 Page:420-428
ISSN:1045-3873
Container-title:Journal of Cardiovascular Electrophysiology
language:en
Short-container-title:Cardiovasc electrophysiol

Author:

Trolese Luca¹²,Dall'Aglio Pietro Bernardo¹³^ORCID,Steinfurt Johannes¹,Gressler Alexander¹,Faber Thomas¹,Cipriani Alberto³,Migliore Federico³,Westermann Dirk¹,Hilgendorf Ingo¹,Jäckel Markus¹^ORCID,

Affiliation:

1. Department of Cardiology and Angiology, Faculty of Medicine, Heart Center Freiburg University University of Freiburg Freiburg Germany

2. Department of Rhythmology Ortenau Klinikum Offenburg‐Lahr Lahr Germany

3. Department of Cardiac, Thoracic, Vascular Sciences and Public Health University of Padova Padova Italy

Publisher

Wiley

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jce.15762

Reference28 articles.

1. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

2. Safety and Efficacy of a Totally Subcutaneous Implantable-Cardioverter Defibrillator

3. 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing

4. Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE)

5. Defibrillation testing during implantation of the subcutaneous implantable cardioverter-defibrillator: a necessary standard or becoming redundant?